Karyopherins: Potential biological elements involved in the delayed graft function in renal transplant recipients

BMC Medical Genomics

Volumn 7, Issue 1, 2014, Pages

  Zaza, Gianluigi ^a   Rascio, Federica ^b   Pontrelli, Paola ^b   Granata, Simona ^a   Stifanelli, Patrizia ^c   Accetturo, Matteo ^b   Ancona, Nicola ^c   Gesualdo, Loreto ^b   Lupo, Antonio ^a   Grandaliano, Giuseppe ^d  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c INSTITUTE OF INTELLIGENT SYSTEMS FOR AUTOMATION   (Italy)

^d UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Delayed graft function; Microarray; Renal transplantation

Indexed keywords

INTERLEUKIN 6; KARYOPHERIN; KARYOPHERIN ALPHA; STAT PROTEIN; STAT3 PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DOWN REGULATION; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY TRANSPLANTATION; MALE; MOLECULAR PATHOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN MICROARRAY; UPREGULATION;

CELL NUCLEUS; DELAYED GRAFT FUNCTION; DEMOGRAPHY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKIN-6; KARYOPHERINS; KIDNEY TRANSPLANTATION; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PHOSPHORYLATION; PRINCIPAL COMPONENT ANALYSIS; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTOME;

EID: 84898470711     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-7-14     Document Type: Article

References (50)

1. Changes in quality of life after renal transplantation. Jofre R, Lopez-Gomez JM, Moreno F, Sanz-Guajardo D, Valderrabano F, Am J Kidney Dis 1998 32 93 100 10.1053/ajkd.1998.v32.pm9669429 9669429 (Pubitemid 28311876)
2. Post kidney transplant quality of life prediction models. Hathaway DK, Winsett RP, Johnson C, Tolley EA, Hartwig M, Milstead J, Wicks MN, Gaber AO, Clin Transplant 1998 12 168 174 9642506 (Pubitemid 28269237)
3. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K, JAMA 1993 270 1339 1343 10.1001/jama.1993.03510110079036 8360969 (Pubitemid 23267894)
4. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. Schnuelle P, Lorenz D, Trede M, Van Der Woude FJ, J Am Soc Nephrol 1998 9 2135 2141 9808102 (Pubitemid 28482164)
5. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D, Klarenbach S, Gill J, Am J Transplant 2011 11 2093 2109 10.1111/j.1600-6143.2011.03686.x 21883901
6. Early metabolic changes in peripheral blood cells of renal transplant recipients treated with cyclosporine A. Rezzani R, Rodella L, Bianchi R, Int J Immunopharmacol 1999 21 455 462 10454019 (Pubitemid 29306927)
7. Pretransplant inflammation: a risk factor for delayed graft function? Lauzurica R, Pastor MC, Bayes B, Hernandez JM, Bonet J, Dolade M, Navarro M, Romero R, J Nephrol 2008 21 221 228 18446717
8. Immunosuppressive drugs for kidney transplantation. Halloran PF, N Engl J Med 2004 351 2715 2729 10.1056/NEJMra033540 15616206 (Pubitemid 39665325)
9. Delayed graft function in the kidney transplant. Siedlecki A, Irish W, Brennan DC, Am J Transplant 2011 11 2279 2296 10.1111/j.1600-6143.2011.03754.x 21929642
10. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US renal transplant mycophenolate mofetil study group. Sollinger HW, Transplant 1995 60 225 232 10.1097/00007890- 199508000-00003
11. Induction antibody therapy in kidney transplantation. Padiyar A, Augustine JJ, Hricik DE, Am J Kidney Dis 2009 54 935 944 10.1053/j.ajkd.2009.06. 020 19682780
12. Delayed graft function in kidney transplantation. Perico N, Cattaneo D, Sayegh MH, Remuzzi G, Lancet 2004 364 1814 1827 10.1016/S0140-6736(04)17406-0 15541456 (Pubitemid 39488068)
13. Delayed graft function in renal transplantation: etiology, management and long-term significance. Shoskes DA, Halloran PF, J Urol 1996 155 1831 1840 10.1016/S0022-5347(01)66023-3 8618268 (Pubitemid 26144066)
14. The nature of renal cell injury. Edelstein CL, Ling H, Schrier RW, Kidney Int 1997 51 1341 1351 10.1038/ki.1997.183 9150442 (Pubitemid 27239881)
15. Major effects of delayed graft function and cold ischaemia time on renal allograft survival. Quiroga I, McShane P, Koo DD, Gray D, Friend PJ, Fuggle S, Darby C, Nephrol Dial Transplant 2006 21 1689 1696 10.1093/ndt/gfl042 16490743 (Pubitemid 44063135)
16. Ischemia-reperfusion induces glomerular and tubular activation of proinflammatory and antiapoptotic pathways: differential modulation by rapamycin. Loverre A, Ditonno P, Crovace A, Gesualdo L, Ranieri E, Pontrelli P, Stallone G, Infante B, Schena A, Di Paolo S, Capobianco C, Ursi M, Palazzo S, Battaglia M, Selvaggi FP, Schena FP, Grandaliano G, J Am Soc Nephrol 2004 15 2675 2686 10.1097/01.ASN.0000139932.00971.E4 15466272 (Pubitemid 41103374)
17. Ischemia-reperfusion injury activates innate immunity in rat kidneys. Ischemia-reperfusion injury activates innate immunity in rat kidneys. Kim BS, Lim SW, Li C, Kim JS, Sun BK, Ahn KO, Han SW, Kim J, Yang CW, Transplant 2005 79 1370 1377 10.1097/01.TP.0000158355.83327.62 (Pubitemid 40740256)
18. T helper 1, 2 and 17 cell subsets in renal transplant patients with delayed graft function. Loverre A, Divella C, Castellano G, Tataranni T, Zaza G, Rossini M, Ditonno P, Battaglia M, Palazzo S, Gigante M, Ranieri E, Schena FP, Grandaliano G, Transpl Int 2011 24 233 242 10.1111/j.1432-2277.2010.01157.x 21281362
19. Clinical determinants of multiple acute rejection episodes in kidney transplant recipients. Humar A, Payne WD, Sutherland DE, Matas AJ, Transplant 2000 69 2357 2360 10.1097/00007890-200006150-00024 (Pubitemid 30409003)
20. Delayed renal graft function: risk factors and impact on the outcome of transplantation. Moreira P, Sá H, Figueiredo A, Mota A, Transplant Proc 2011 43 100 105 10.1016/j.transproceed.2010.12.023 21335164
21. The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidase. Dell'Oglio MP, Zaza G, Rossini M, Divella C, Pontrelli P, Verrienti R, Rutigliano M, Ditonno P, Stifanelli P, Ancona N, Schena FP, Grandaliano G, J Am Soc Nephrol 2010 21 2157 2168 10.1681/ASN.2010020181 20864690
22. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP, Proc Natl Acad Sci USA 2005 102 15545 15550 10.1073/pnas.0506580102 16199517 (Pubitemid 41528093)
23. Long-term survival in renal transplant recipients with graft function. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK, Kidney Int 2000 57 307 313 10.1046/j.1523-1755.2000.00816.x 10620213 (Pubitemid 30227779)
24. Delayed graft function: risk factors and implications for renal allograft survival. Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL, Transplant 1997 63 968 974 10.1097/00007890-199704150-00011 (Pubitemid 27173019)
25. Long-term results of 1047 cadaveric kidney transplantations with special emphasis on initial graft function and rejection. Kyllönen LE, Salmela KT, Eklund BH, Halme LE, Höckerstedt KA, Isoniemi HM, Mäkisalo HJ, Ahonen J, Transpl Int 2000 13 122 128 10.1111/j.1432-2277.2000.tb01051.x 10836648 (Pubitemid 30417367)
26. Risk factors for delayed graft function in cadaveric kidney transplantation: a prospective study of renal function and graft survival after preservation with University of Wisconsin solution in multi-organ donors. European multicenter study group. Koning OH, Ploeg RJ, van Bockel JH, Groenewegen M, van der Woude FJ, Persijn GG, Hermans J, Transplant 1997 63 1620 1628 10.1097/00007890-199706150-00015 (Pubitemid 27265505)
27. Serum neutrophil gelatinase-associated lipocalin and interleukin-18 as predictive biomarkers for delayed graft function after kidney transplantation. Lee EY, Kim MS, Park Y, Kim HS, J Clin Lab Anal 2012 26 295 301 10.1002/jcla.21520 22811364
28. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Parikh CR, Jani A, Mishra J, Ma Q, Kelly C, Barasch J, Edelstein CL, Devarajan P, Am J Transplant 2006 6 1639 1645 10.1111/j.1600-6143.2006.01352.x 16827865 (Pubitemid 43945804)
29. Serum aminoacylase-1 is a novel biomarker with potential prognostic utility for long-term outcome in patients with delayed graft function following renal transplantation. Welberry Smith MP, Zougman A, Cairns DA, Wilson M, Wind T, Wood SL, Thompson D, Messenger MP, Mooney A, Selby PJ, Lewington AJ, Banks RE, Kidney Int 2013 84 1214 1225 10.1038/ki.2013.200 23739232
30. Prediction of delayed graft function by means of a novel web-based calculator: a single-center experience. Rodrigo E, Miñambres E, Ruiz JC, Ballesteros A, Piñera C, Quintanar J, Fernández-Fresnedo G, Palomar R, Gómez-Alamillo C, Arias M, Am J Transplant 2012 12 240 244 10.1111/j.1600-6143.2011.03810.x 22026730
31. Predictive ability of pretransplant comorbidities to predict long-term graft loss and death. Machnicki G, Pinsky B, Takemoto S, Balshaw R, Salvalaggio PR, Buchanan PM, Irish W, Bunnapradist S, Lentine KL, Burroughs TE, Brennan DC, Schnitzler MA, Am J Transplant 2009 9 494 505 10.1111/j.1600-6143.2008.02486.x 19120083
32. Pretransplant transcriptome profiles identify among kidneys with delayed graft function those with poorer quality and outcome. Mas VR, Scian MJ, Archer KJ, Suh JL, David KG, Ren Q, Gehr TW, King AL, Posner MP, Mueller TF, Maluf DG, Mol Med 2011 17 1311 1322 10.1007/s00894-010-0825-2 21912807
33. The transcriptome of the implant biopsy identifies donor kidneys at increased risk of delayed graft function. Mueller TF, Reeve J, Jhangri GS, Mengel M, Jacaj Z, Cairo L, Obeidat M, Todd G, Moore R, Famulski KS, Cruz J, Wishart D, Meng C, Sis B, Solez K, Kaplan B, Halloran PF, Am J Transplant 2008 8 78 85 18021287
34. Towards reconciling structure and function in the nuclear pore complex. Lim RY, Aebi U, Fahrenkrog B, Histochem Cell Biol 2008 129 105 116 10.1007/s00418-007-0371-x 18228033
35. Transport routes through the nuclear pore complex. Pemberton LF, Blobel G, Rosenblum JS, Curr Opin Cell Biol 1998 10 392 399 10.1016/S0955-0674(98) 80016-1 9640541 (Pubitemid 28287051)
36. Nanoscale mechanism of molecular transport through the nuclear pore complex as studied by scanning electrochemical microscopy. Kim J, Izadyar A, Nioradze N, Amemiya S, J Am Chem Soc 2013 135 2321 2329 10.1021/ja311080j 23320434
37. Regulated nuclear import of the STAT1 transcription factor by direct binding of importin-alpha. McBride KM, Banninger G, McDonald C, Reich NC, EMBO J 2002 21 1754 1763 10.1093/emboj/21.7.1754 11927559 (Pubitemid 34614631)
38. The ins and outs of STAT1 nuclear transport. McBride KM, Reich NC, Sci STKE 2003 195 E13
39. Importin alpha nuclear localization signal binding sites for STAT1, STAT2, and influenza A virus nucleoprotein. Melen K, Fagerlund R, Franke J, Kohler M, Kinnunen L, Julkunen I, J Biol Chem 2003 278 28193 28200 10.1074/jbc.M303571200 12740372 (Pubitemid 36900019)
40. Nucleocytoplasmic shuttling of STAT transcription factors. Meyer T, Vinkemeier U, Eur J Biochem 2004 271 4606 4612 10.1111/j.1432-1033.2004.04423.x 15606747 (Pubitemid 40065563)
41. Nuclear transport: never-ending cycles of signals and receptors. Barry DM, Wente SR, Essays Biochem 2000 36 89 103 12471905
42. The molecular mechanism of transport of macromolecules through nuclear pore complexes. Bayliss R, Corbett AH, Stewart M, Traffic 2000 1 448 456 10.1034/j.1600-0854.2000.010602.x 11208130
43. The nuclear pore complex as a transport machine. Rout MP, Aitchison JD, J Biol Chem 2001 276 16593 16596 10.1074/jbc.R100015200 11283009
44. An essential role of the JAK-STAT pathway in ischemic preconditioning. Xuan YT, Guo Y, Han H, Zhu Y, Bolli R, Proc Natl Acad Sci USA 2001 98 9050 9055 10.1073/pnas.161283798 11481471 (Pubitemid 32743867)
45. Blockage of JAK/STAT signalling attenuates renal ischaemia-reperfusion injury in rat. Yang N, Luo M, Li R, Huang Y, Zhang R, Wu Q, Wang F, Li Y, Yu X, Nephrol Dial Transplant 2008 23 91 100 17670769 (Pubitemid 351767355)
46. Transcriptome analysis of renal ischemia/reperfusion injury and its modulation by ischemic pre-conditioning or hemin treatment. Correa-Costa M, Azevedo H, Amano MT, Gonçalves GM, Hyane MI, Cenedeze MA, Renesto PG, Pacheco-Silva A, Moreira-Filho CA, Câmara NO, PLoS One 2012 7 49569 10.1371/journal.pone.0049569 23166714
47. Role of transcription factors in small intestinal ischemia-reperfusion injury and tolerance induced by ischemic preconditioning. Takeshita M, Tani T, Harada S, Hayashi H, Itoh H, Tajima H, Ohnishi I, Takamura H, Fushida S, Kayahara M, Transplant Proc 2010 42 3406 3413 10.1016/j.transproceed.2010.06.038 21094787
48. Importazole, a small molecule inhibitor of the transport receptor importin-β Soderholm JF, Bird SL, Kalab P, Sampathkumar Y, Hasegawa K, Uehara-Bingen M, Weis K, Heald R, ACS Chem Biol 2011 6 700 708 10.1021/cb2000296 21469738
49. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA, Biochem J 2012 443 851 856 10.1042/BJ20120150 22417684
50. An AlphaScreen®-based assay for high-throughput screening for specific inhibitors of nuclear import. Wagstaff KM, Rawlinson SM, Hearps AC, Jans DA, J Biomol Screen 2011 16 192 200 10.1177/1087057110390360 21297106